Lyterian Therapeutics

Lyterian Therapeutics is a private, preclinical-stage biotech founded in 2020 and headquartered in South San Francisco, California. The company is pioneering a novel drug discovery platform that leverages endogenous protein homeostatic mechanisms—the body's natural systems for maintaining protein balance—to target genetically-validated drivers of disease, with an initial focus on neuroscience and rare disorders. Backed by a founding team of renowned academic scientists from Stanford, UC Berkeley, and Genentech, Lyterian is building its research team to translate fundamental biological insights into first-in-class medicines. The company is currently in a pre-revenue, asset discovery and development phase.

A drug discovery platform focused on co-opting endogenous protein homeostatic mechanisms (e.g., quality control, degradation, stabilization pathways) to precisely regulate genetically-validated disease targets.

Lyterian operates in the competitive space of novel modality drug discovery, particularly intersecting with companies focused on targeted protein degradation (e.g., Arvinas, Kymera Therapeutics), molecular glues, and protein homeostasis. It must differentiate its specific biological approach against well-funded peers and large pharmaceutical internal efforts.